| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2009;120:1616-1622.)
© 2009 American Heart Association, Inc.
Vascular Medicine |
From the Department of Experimental Medicine, Divisione I Clinica Medica (F.V., R.C., P.P., S.B., L.L.), and Center of Clinic Lipid Research, Department of Pediatrics (F.M.), University of Rome "La Sapienza," Rome; Department of Internal Medicine, University of Rome "Tor Vergata," Rome (V.S., P.R., A.F.); Department of Pediatrics and Institute of Molecular Medicine "A. Nocivelli," University of Brescia, Brescia (A.P., A.R.S.); Department of Pediatrics, University of Naples, Naples (C.P.); Department of Biomedicine and Evolutive Aging, University of Bari, Bari (D.D.M., B.M.); IRCSS Foundation, University of Milan, Milan (M.C.P.); Department of Pediatrics, University of Turin, Turin (S.M.); and Department of Pediatrics, University of Florence, Florence (E.G.).
Correspondence to Professor Francesco Violi, Divisione I Clinica Medica, Viale del Policlinico 155, Roma, 00161, Italy. E-mail francesco.violi{at}uniroma1.it
Received May 2, 2009; accepted July 31, 2009.
Background— NADPH oxidase is believed to modulate arterial tone, but its role in humans is still unclear. The objective of this study was to evaluate whether NADPH oxidase is involved in flow-mediated arterial dilation (FMD).
Methods and Results— Twenty-five patients with hereditary deficiency of gp91phox, the catalytic core of NADPH oxidase, (X-CGD), 25 healthy subjects, and 25 obese patients matched for sex and age were recruited. FMD, platelet gp91phox, serum levels of nitrite and nitrate as markers of nitric oxide generation, oxidized low-density lipoprotein, and urinary excretion of isoprostanes as markers of oxidative stress were determined. Platelet gp91phox expression was downregulated in X-CGD patients (1.0±0.8 mean fluorescence; P<0.001) and upregulated in obese patients (4.1±2.2 mean fluorescence; P=0.01) compared with healthy subjects (2.9±1.7 mean fluorescence). Urinary excretion of isoprostanes was reduced in X-CGD patients (41.7±33.3 pg/mg creatinine; P=0.04) and increased in obese patients (154.4±91 pg/mg creatinine; P<0.001) compared with healthy subjects (69.5±52.4 pg/mg creatinine). Obese patients had higher serum oxidized low-density lipoprotein than healthy subjects (35.3±6.7 versus 24.8±9.8 U/L; P<0.001) and X-CGD patients (28.5±7.2 U/L; P<0.001). X-CGD patients had significantly higher FMD (14.7±5.9%) compared with healthy subjects (7.9±2.5%; P<0.001); obese patients had lower FMD (5.3±3.0%; P=0.028) compared with healthy subjects. Serum nitrite and nitrate levels were significantly higher in patients with X-CGD (36.0±10.8 µmol/L; P=0.016) and lower in obese patients (9.3±11.0 µmol/L; P=0.001) compared with healthy subjects (27.1±19.1 µmol/L). Serum nitrite and nitrate levels significantly correlated with FMD (Rs=0.403, P<0.001) and platelet gp91phox (Rs=–0.515, P<0.001). FMD inversely correlated with platelet gp91phox (Rs=–0.502, P<0.001) and isoprostanes (Rs=–0.513, P<0.001).
Conclusion— This study provides the first evidence that, in humans, gp91phox is implicated in the modulation of arterial tone.
Related Article:
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |